Araujo S V, Bond J B, Wilson R P, Moster M R, Schmidt C M, Spaeth G L
William and Anna Goldberg Glaucoma Service and Research Laboratories, Wills Eye Hospital, Jefferson Medical College, Philadelphia, USA.
Br J Ophthalmol. 1995 Dec;79(12):1098-101. doi: 10.1136/bjo.79.12.1098.
To evaluate the effect of the chronic use of apraclonidine 0.5% on the intraocular pressure (IOP) of patients with glaucoma; also, to study the side effect profile of this drug when used chronically.
All patients who had uncontrolled IOP, who were either already on glaucoma medications, or who were intolerant of other glaucoma medications were enrolled. A total of 185 patients were started on apraclonidine 0.5% two to three times a day in one eye.
Follow up extended to 35 weeks. The mean difference in IOP between treated and control eyes was 2.1 (SD 5.0) mm Hg. A similar IOP lowering effect was obtained comparing IOP difference from baseline in the treated eye only.
By the end of the follow up period, 46% of patients were still on the medication. The drug was stopped in 23% of patients because of side effects and in 31% of patients because of failure to lower IOP significantly.
评估长期使用0.5%阿可乐定对青光眼患者眼压(IOP)的影响;同时,研究该药物长期使用时的副作用情况。
纳入所有眼压控制不佳的患者,这些患者要么已经在使用青光眼药物,要么对其他青光眼药物不耐受。总共185例患者开始在一只眼中每天使用2至3次0.5%阿可乐定。
随访期延长至35周。治疗眼与对照眼之间的眼压平均差值为2.1(标准差5.0)毫米汞柱。仅比较治疗眼与基线眼压差值时,也获得了类似的眼压降低效果。
到随访期结束时,46%的患者仍在使用该药物。23%的患者因副作用停药,31%的患者因眼压未显著降低停药。